Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing novel immunology therapies for autoimmune and chronic inflammatory diseases [3] - The company's lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator currently being evaluated in two Phase 2b clinical trials, one for atopic dermatitis and another for alopecia areata [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3] Upcoming Events - Nektar Therapeutics will host an investor call and live webcast on June 24, 2025, to review top-line data from the 16-week induction period of the Phase 2b REZOLVE-AD clinical trial for rezpegaldesleukin [1] - The data will be released in a morning press release and presented during the webcast, with access details available on the Nektar website [2]